AnaptysBio, Inc.
General ticker "ANAB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $632.9M (TTM average)
AnaptysBio, Inc. follows the US Stock Market performance with the rate: 40.9%.
Estimated limits based on current volatility of 3.3%: low 41.54$, high 44.35$
Factors to consider:
- Total employees count: 136 (+16.2%) as of 2024
- Top business risk factors: Manufacturing process failures, Insufficient funding, Supply chain disruptions, Regulatory and compliance, Market volatility
- Current price 82.5% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.52$, 23.73$]
- 2025-12-31 to 2026-12-31 estimated range: [7.64$, 19.38$]
Financial Metrics affecting the ANAB estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -34.06 <= 0.33
- Positive: Investing cash flow per share per price, % of 24.01 > -0.66
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: Shareholder equity ratio, % of 14.65 <= 18.93
Short-term ANAB quotes
Long-term ANAB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $10.29MM | $17.16MM | $91.28MM |
| Operating Expenses | $125.44MM | $181.57MM | $206.23MM |
| Operating Income | $-115.15MM | $-164.41MM | $-114.95MM |
| Non-Operating Income | $-13.55MM | $0.79MM | $-30.28MM |
| Interest Expense | $21.11MM | $18.08MM | $50.09MM |
| R&D Expense | $88.80MM | $139.62MM | $163.84MM |
| Income(Loss) | $-128.70MM | $-163.62MM | $-145.23MM |
| Taxes | $0.02MM | $-0.00MM | $0.00MM |
| Profit(Loss)* | $-128.72MM | $-163.62MM | $-145.23MM |
| Stockholders Equity | $262.10MM | $88.10MM | $70.87MM |
| Assets | $610.38MM | $452.39MM | $483.83MM |
| Operating Cash Flow | $-73.59MM | $-120.80MM | $-135.34MM |
| Capital expenditure | $0.36MM | $0.81MM | $0.36MM |
| Investing Cash Flow | $-394.85MM | $144.75MM | $95.40MM |
| Financing Cash Flow | $44.02MM | $-59.30MM | $127.05MM |
| Earnings Per Share** | $-4.57 | $-6.08 | $-5.12 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.